SpineVision is a privately owned, commercial-stage spinal technology company that develops and markets implants and instrumentation for a wide range of spinal pathologies. The company has designed products since its founding in 1999 and recently received CE marking for its Flex+2 dynamic stabilization rod and 510(k) clearance for a range of minimally invasive surgical instrumentation. SpineVision operates in France, Italy, Benelux, the UK and the United States and maintains distribution agreements in additional territories. Management reports double-digit revenue growth in 2012 with strong growth continuing into Q1 2013. The company plans to use new capital to expand existing commercial operations primarily in the U.S., grow activities in Europe, strengthen R&D and develop an innovative approach to its supply chain. Leadership has stated the objective to further grow revenue and achieve sustainable profitability. SpineVision develops and commercializes next-generation spinal surgery devices, notably the minimally invasive LUMIS system and the motion-preservation Flex+ hybrid-rod system. The company positions Flex+ to provide both rigid fusion support and dynamic stabilization via a single low-profile implant, and LUMIS to enable minimally invasive screw placement. SpineVision says its products aim to reduce large incisions and improve patient outcomes while protecting adjacent discs. The company reports strong engagement with key opinion leaders and surgeons who are using Flex+ together with LUMIS across stages of disc degeneration. SpineVision is privately owned, headquartered in Paris, and maintains subsidiaries in the USA, Italy, the UK and Belgium. The recent $5 million cash infusion is intended primarily to accelerate market penetration of these next-generation devices.

Total raised

$15M

Funding rounds

2

Latest round

Equity

Latest activity

May 2013